medigraphic.com

2024, Number 1

<< Back Next >>

Rev Fac Med UNAM 2024; 67 (1)

Buschke-Löwenstein Tumor in Adolescent Pregnancy

Sotres GAI, Adame CJE

Language: Spanish
References: 26
Page: 22-27
PDF size: 287.02 Kb.


ABSTRACT

Buschke-Löwenstein tumor also called giant condyloma acuminatum is a rare condition due to the human papillomavirus with an incidence of 0.01% and just 6 cases reported in pregnancy. There is no consensus on the treatment, although surgery has been the most reported.
Clinical case: A 14 year-old primigravid patient with a 21- week pregnancy who was admitted to the Emergency Department due to a perineal painful tumor which appeared 5 months before. On physical examination two irregular exophytic, cauliflower-like and ulcerated lesions of 20 × 10 cm of size each one with malodorous discharge were found on her perineal region suggestive of giant condyloma acuminatum. We decided to resect the tumor with tumor-free margin control and healing per secundam. The pathology report showed a giant condyloma acuminatum with tumor-free margin. The PCR analysis revealed human papillomavirus genotype 53. Complete epithelialization was noted at 12 weeks with no complications noted.
Conclusion: Buschke-Löwenstein tumor is considered as a benign tumor, but it carries a risk of malignant transformation and it can appear after treatment, which makes important to strengthen the prevention and screening of human papillomavirus.


REFERENCES

  1. Prevención, detección, diagnóstico y tratamiento de lesionesprecursoras del cáncer de cuello uterino en primery segundo nivel de atención. Guía de Evidencias y Recomendaciones:Guía de Práctica clínica. 2018. [Consulta el 20 de mayo 2023]. Disponible en: http://cenetec-difusion.com/CMGPC/GPC-SS-146-18/ER.pdf

  2. Juárez-González K, Paredes-Cervantes V, Martínez-SalazarM, Gordillo-Rodríguez S, Vera-Arzave C, Martínez-Meraz M, et al. Prevalencia del virus del papiloma humanooncogénico en pacientes con lesión cervical [Prevalence ofoncogenic human papillomavirus in patients with cervicallesion]. Rev Med Inst Mex Seguro Soc. 2020;58:243-249.doi:10.24875/RMIMSS.M20000027

  3. Malek-Mellouli M, Ben Amara F, Fatnassi A, Reziga H.Giant condyloma in pregnancy. Tunis Med. 2013;91:422-

  4. 423.4. Illades-Aguiar B, Cortés-Malagón EM, Antonio-VéjarV, Zamudio-López N, Alarcón-Romero LC, Fernández-Tilapa G, et al. Cervical carcinoma in Southern Mexico:Human papillomavirus and cofactors. Cancer Detect Prev.2009;32(4):300-307. doi:10.1016/j.cdp.2008.09.001.

  5. Crespo R, Puig F, Lanzon A, Borell A. Buschke-Lowensteintumor and pregnancy: a case report. Eur J GynaecolOncol. 2007;28:328-329.

  6. Garozzo G, Nuciforo G, Rocchi CM, Bonanno NM,Sampugnaro EG, Piccione S, et al. Büschke-Lowensteintumour in pregnancy. Eur J Obstet Gynecol Reprod Biol.2003;111:88-90. doi:10.1016/s0301-2115(03)00112-x

  7. De Sanjosé S, Brotons M, Pavón MA. The natural historyof human papillomavirus infection. Best Pract ResClin Obstet Gynaecol. 2018;47:2-13. doi:10.1016/j.bpobgyn.2017.08.015

  8. Riethmuller D, Buisson A, Thong Vanh C, Istasse F, Valmary-Degano S, Michy T, et al. La tumeur de BuschkeLowenstein chez la femme enceinte [Giant condylomaacuminatum in pregnancy]. Gynecol Obstet Fertil Senol.2022;50:201-204. doi:10.1016/j.gofs.2021.08.001

  9. Cui T, Huang J, Lv B, Yao Q. Giant condyloma acuminatumin pregnancy: A case report. Dermatol Ther.2019;32:e12972. doi:10.1111/dth.12972

  10. Michiels I, Tjalma WA. The rapid development of a giantcondyloma acuminatum (Buschke-Löwenstein tumor) duringpregnancy. Acta Obstet Gynecol Scand. 2007;86:762-763. doi:10.1080/00016340600617999

  11. Spinu D, Rădulescu A, Bratu O, Checheriţă IA, RanettiAE, Mischianu D. Giant condyloma acuminatum - Buschke-Lowenstein disease - a literature review. Chirurgia(Bucur). 2014;109:445-450.

  12. Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA,Zhou Y, et al. Epidemiology and Burden of Human Papillomavirusand Related Diseases, Molecular Pathogenesis,and Vaccine Evaluation. Front Public Health. 2021;8:552028. doi:10.3389/fpubh.2020.552028

  13. Manlubatan S, Onglao M, Tampo M, Lopez M. Outcomesof surgical management of buschke-lowenstein tumor in aPhilippine tertiary hospital. Ann Coloproctol. 2022;38:82-87. doi:10.3393/ac.2020.00731.0104

  14. Cuenca C, Álvarez-Palencia C, Ojeda D, Martínez M,Luna S, Martínez C. Condiloma acuminado gigante (tumorde Buschke-Löwenstein). Progresos de Obstetricia yGinecología. 2010;53:315-319.

  15. Purzycka-Bohdan D, Nowicki RJ, Herms F, CasanovaJL, Fouéré S, Béziat V. The Pathogenesis of Giant CondylomaAcuminatum (Buschke-Lowenstein Tumor): AnOverview. Int J Mol Sci. 2022;23:45-47. doi:10.3390/ijms23094547

  16. Nieves-Condoy JF, Acuña-Pinzón CL, Chavarría-ChaviraJL, Hinojosa-Ugarte D, Zúñiga-Vázquez LA. GiantCondyloma Acuminata (Buschke-Lowenstein Tumor):Review of an Unusual Disease and Difficult to Manage.Infect Dis Obstet Gynecol. 2021;2021:9919446. doi:10.1155/2021/9919446

  17. Boda D, Cutoiu A, Bratu D, Bejinariu N, Crutescu R.Buschke-Löwenstein tumors: A series of 7 case reports.Exp Ther Med. 2022;23:393. doi:10.3892/etm.2022.11320

  18. Akhavizadegan H. Electrocautery resection, shaving with ascalpel, and podophyllin: a combination therapy for giantcondyloma acuminatum. World J Mens Health. 2015;33:39-41. doi:10.5534/wjmh.2015.33.1.39

  19. Badiu DC, Manea CA, Mandu M, Chiperi V, Marin IE,Mehedintu C, et al. Giant Perineal Condyloma Acuminatum(Buschke-Lowenstein Tumour): A Case Report.Chirurgia (Bucur). 2016;111:435-438. doi:10.21614/chirurgia.111.5.435

  20. Combaud V, Verhaeghe C, El Hachem H, Legendre G,Descamps P, Martin L, et al. Giant condyloma acuminatumof the vulva: Successful management with imiquimod.JAAD Case Rep. 2018;4:692-694. doi:10.1016/j.jdcr.2018.04.007

  21. Geusau A, Heinz-Peer G, Volc-Platzer B, Stingl G, KirnbauerR. Regression of deeply infiltrating giant condyloma(Buschke-Löwenstein tumor) following long-termintralesional interferon alfa therapy. Arch Dermatol. 2000;136:707-710. doi:10.1001/archderm.136.6.707

  22. Secretaría de Salud. Actualización de esquema de vacunacióncontra virus del papiloma humano (VPH) en niñas/adolescentes femeninas y en la población de mujeres cis ytrans que viven con VIH. 2022. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/778784/NUEVO_ESQUEMA_VPH.pdf [Consulta el 20 de mayo2023].

  23. World Health Organization. One-dose Human Papillomavirus(HPV) vaccine offers solid protection against cervicalcancer. 2022. [Consultado el 22 de mayo 2023]. Disponibleen: https://www.who.int/news/item/11-04-2022-onedose-human-papillomavirus-(hpv)-vaccine-offers-solidprotection-against-cervical-cancer

  24. Giannone G, Giuliano AR, Bandini M, Marandino L,Raggi D, Earle W, et al. HPV vaccination and HPV-relatedmalignancies: impact, strategies and optimizationstoward global immunization coverage. Cancer Treat Rev.2022;111:102467. doi: 10.1016/j.ctrv.2022.102467

  25. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, LörinczA, Wheeler CM, et al. HPV vaccination impact ona cervical cancer screening program: methods of theFASTER-Tlalpan Study in Mexico. Salud Publica Mex.2016;58:211-9. doi: 10.21149/spm.v58i2.7790

  26. Bruni L, Serrano B, Bosch X, Castellsagué X. Vacunafrente al virus del papiloma humano. Eficacia y seguridad[Human papillomavirus vaccine. Efficacy and safety].Enferm Infecc Microbiol Clin. 2015;33:342-54. doi:10.1016/j.eimc.2015.03.018




2020     |     www.medigraphic.com